Systemic Infections clinical trials

Explore recruiting systemic infections clinical trials.

Recruiting systemic infections studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Systemic Infections trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Early Model-Informed Precision Dosing of beta-lactam antibiotics in critically ill children: big solution for small people?

Belgium

Therapeutic use (Phase IV) EU CTIS Study details

Randomized Clinical Trial for the Treatment of Lateral Epicondylitis with Debridement Arthroscopic Versus Cytokine-Rich Autologous Serum. (SARC)

Spain

Therapeutic use (Phase IV) EU CTIS Study details

A 12-month, randomized, single-blind, placebo-controlled exposure-response study of TCD601 (siplizumab) in new onset type 1 diabetes patients (STRIDE)

Sweden, Belgium, Italy, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Safety, Tolerability and Feasibility of Treatment with GP120-activated Regulatory T cells (ATreg) Early After Haematopoietic Stem Cell Transplantation (HSCT) to Reduce the Incidence and Severity of Acute Graft vs Host Disease (GvHD)

Germany

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Efficacy of Higher vs. Lower Doses of Dexamethasone in Patients With Acute Hypoxemic Respiratory Failure (Including ARDS) Caused by Infections (Including COVID-19)

Spain

Therapeutic use (Phase IV) EU CTIS Study details

A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study, Followed by an Active Treatment Phase to Evaluate the Efficacy and Safety of Apremilast in Children From 2 to Less Than 18 Years of Age With Active Oral Ulcers Associated With Behçet's Disease (BEAN)

Italy, Greece, France, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

Systemic Infections trials by city

Systemic Infections clinical trials

Recruiting systemic infections studies right now

Beta-lactam Intermittent Versus Continuous Infusion and Combination Antibiotic Therapy in Sepsis

Adjunctive Fludrocortisone in Septic Shock

Study SOLACE SEPSIS

External Drainage of Thoracic Duct Lymph to Reduce Inflammatory Cytokines in Septic Shock Patients

Candida PCR Diagnosis Strategy in Patients From Intensive Care Units

Reducing Systemic Inflammation in People on Antiretroviral Therapy

Impact of Vascular Calcification and CASR Expression by Monocytes in Septic Shock

Clinical Effects of Ringers Lactate Versus Sterofundin/ Plasmalyte Solution in Patients With Sepsis

The Preventive Effect of Shenfu Injection on Myocardial Dysfunction in Sepsis

UMMS Sepsis Early Prediction Score (SEPSys) and RESCUE Score Combined Clinical Trial

Effect of Interferon Gamma as a Treatment for Post-aggressive Immunosuppression in Intensive Care Units, a Randomized Bayesian Double-blind Controlled Trial Versus Placebo

3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer

Also recruiting in Europe

Early Model-Informed Precision Dosing of beta-lactam antibiotics in critically ill children: big solution for small people?

Randomized Clinical Trial for the Treatment of Lateral Epicondylitis with Debridement Arthroscopic Versus Cytokine-Rich Autologous Serum. (SARC)

A 12-month, randomized, single-blind, placebo-controlled exposure-response study of TCD601 (siplizumab) in new onset type 1 diabetes patients (STRIDE)

Safety, Tolerability and Feasibility of Treatment with GP120-activated Regulatory T cells (ATreg) Early After Haematopoietic Stem Cell Transplantation (HSCT) to Reduce the Incidence and Severity of Acute Graft vs Host Disease (GvHD)

Efficacy of Higher vs. Lower Doses of Dexamethasone in Patients With Acute Hypoxemic Respiratory Failure (Including ARDS) Caused by Infections (Including COVID-19)

A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study, Followed by an Active Treatment Phase to Evaluate the Efficacy and Safety of Apremilast in Children From 2 to Less Than 18 Years of Age With Active Oral Ulcers Associated With Behçet's Disease (BEAN)

Systemic Infections trials by city

Other conditions